Are scores useful in advanced heart failure?

References

• Rosamond W, Flegal K, Furie K et al. Heart Disease and Stroke Statistics – 2008 Update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation117(4), E25–E146 (2008).
   PubMed Web of Science ®Google Scholar
• Bleumink GS, Knetsch AM, Sturkenboom MCJM et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure: The Rotterdam Study. Eur. Heart J.25(18), 1614–1619 (2004).
   PubMed Web of Science ®Google Scholar
• Krum H, Gilbert RE. Demographics and concomitant disorders in heart failure. Lancet362, 147–158 (2003).
   PubMed Web of Science ®Google Scholar
• Solomon SD, Dobson J, Pocock S et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation116(13), 1482–1487 (2007).
   PubMed Web of Science ®Google Scholar
• Pocock SJ, Wang D, Pfeffer MA et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur. Heart J.27(1), 65–75 (2006).
   PubMed Web of Science ®Google Scholar
• Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am. Heart J.154(2), 260–266 (2007).
   PubMed Web of Science ®Google Scholar
• Aaronson KD, Schwartz JS, Chen T-M, Wong K-L, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation95(12), 2660–2667 (1997).
   PubMed Web of Science ®Google Scholar
• Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA290(19), 2581–2587 (2003).
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Adams KF Jr, Abraham WT et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA293(5), 572–580 (2005).
   PubMed Web of Science ®Google Scholar
• Levy WC, Mozaffarian D, Linker DT et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation113(11), 1424–1433 (2006).
   PubMed Web of Science ®Google Scholar
• Rohde LE, Goldraich L, Polanczyk CA et al. A simple clinically based predictive rule for heart failure in-hospital mortality. J. Card. Fail.12(8), 587–593 (2006).
   PubMed Web of Science ®Google Scholar
• O’Connor CM, Abraham WT, Albert NM et al. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am. Heart J.156(4), 662–673 (2008).
   PubMed Web of Science ®Google Scholar
• Abraham WT, Fonarow GC, Albert NM et al. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). J. Am. Coll. Cardiol.52(5), 347–356 (2008).
   PubMed Web of Science ®Google Scholar
• Adams KF, Zannad F. Clinical definition and epidemiology of advanced heart failure. Am. Heart J.135(6), S204–S215 (1998).
   Google Scholar
• ESCAPE Study Coordinators. Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness: the ESCAPE trial. JAMA294(13), 1625–1633 (2005).
   PubMed Web of Science ®Google Scholar
• Mehra MR, Kobashigawa J, Starling RC et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates – 2006. J. Heart Lung Transplant.25(9), 1024–1042 (2006).
   PubMed Web of Science ®Google Scholar
• Metra M, Ponikowski P, Dickstein K et al. Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail.9(6), 684–694 (2007).
   PubMed Web of Science ®Google Scholar
• Peterson LR, Schechtman KB, Ewald GA et al. The effect of β-adrenergic blockers on the prognostic value of peak exercise oxygen uptake in patients with heart failure. J. Heart Lung Transplant.22(1), 70–77 (2003).
   PubMed Web of Science ®Google Scholar
• Lund LH, Aaronson KD, Mancini DM. Predicting survival in ambulatory patients with severe heart failure on β-blocker therapy. Am. J. Cardiol.92(11), 1350–1354 (2003).
   PubMed Web of Science ®Google Scholar
• Koelling TM, Joseph S, Aaronson KD. Heart failure survival score continues to predict clinical outcomes in patients with heart failure receiving β-blockers. J. Heart Lung Transplant.23(12), 1414–1422 (2004).
   PubMed Web of Science ®Google Scholar
• Zugck C, Haunstetter A, Kruger C et al. Impact of β-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure. J. Am. Coll. Cardiol.39(10), 1615–1622 (2002).
   PubMed Web of Science ®Google Scholar
• Arena R, Myers J, Williams MA et al. Assessment of functional capacity in clinical and research setting. A Scientific Statement from the American Heart Association Committee on Exercise, Rehabilitation, and Prevention of the Council on Clinical Cardiology and the Council on Cardiovascular Nursing. Circulation116(3), 329–343 (2007).
   PubMed Web of Science ®Google Scholar
• Pfeffer M, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet362, 759–766 (2003).
   PubMed Web of Science ®Google Scholar
• Mauro F, Nadia A, Cristina C et al. Prognostic value of plasma brain natriuretic peptide, urea nitrogen, and creatinine in outpatients >70 years of age with heart failure. Am. J. Cardiol.96(5), 705–709 (2005).
   PubMed Web of Science ®Google Scholar
• Forman DE, Butler J, Wang Y et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J. Am. Coll. Cardiol.42, 61–67 (2004).
   Google Scholar
• Mozaffarian D, Anker SD, Anand I et al. Prediction of mode of death in heart failure: The Seattle Heart Failure Model. Circulation116(4), 392–398 (2007).
   PubMed Web of Science ®Google Scholar
• May HT, Horne BD, Levy WC et al. Validation of the Seattle Heart Failure Model in a community-based heart failure population and enhancement by adding B-type natriuretic peptide. Am. J. Cardiol.100(4), 697–700 (2007).
   PubMed Web of Science ®Google Scholar
• Philbin EF, DiSalvo TG. Prediction of hospital readmission for heart failure: development of a simple risk score based on administrative data. J. Am. Coll. Cardiol.33(6), 1560–1566 (1999).
   PubMed Web of Science ®Google Scholar
• Fonarow G. Epidemiology and risk stratification in acute heart failure. Am. Heart J.155(2), 200–207 (2008).
   PubMed Web of Science ®Google Scholar
• Felker GM, Adams KF, Konstam MA, O’Connor CM, Gheorghiade M. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am. Heart J.145(2), S18–S25 (2003).
   PubMed Web of Science ®Google Scholar
• Braunwald E. Biomarkers in heart failure. N. Engl. J. Med.358(20), 2148–2159 (2008).
   PubMed Web of Science ®Google Scholar
• Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction. N. Engl. J. Med.340(8), 609–616 (1999).
   PubMed Web of Science ®Google Scholar
• Yancy C. Heart failure in African Americans: a cardiovascular enigma. J. Card. Fail.6(3), 183–186 (2000).
   PubMed Web of Science ®Google Scholar
• Yancy C. Does race matter in heart failure? Am. Heart J.146(2), 203–206 (2003).
   PubMed Web of Science ®Google Scholar
• Gottlieb SS. Prognostic indicators: useful for clinical care? J. Am. Coll. Cardiol.53(4), 343–344 (2009).
   PubMed Web of Science ®Google Scholar
• Liggett S, Mialet-Perez J, Thaneemit-Chen S et al. A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure. Proc. Natl Acad. Sci. USA103(30), 11288–11293 (2006).
   PubMed Web of Science ®Google Scholar
• Eichhorn EJ, Domanski MJ, Krause-Steinrauf H, Bristow MR, Lavori PW; BEST Investigators. A trial of the β-blocker bucindolol in patients with advanced chronic heart failure. N. Engl. J. Med.344(22), 1659–1667 (2001).
   PubMed Web of Science ®Google Scholar
• Kalogeropoulos AP, Georgiopoulou VV, Giamouzis G et al. Utility of the Seattle Heart Failure Model in patients with advanced heart failure. J. Am. Coll. Cardiol.53(4), 334–342 (2009).
   PubMed Web of Science ®Google Scholar
• Myers J, Gullestad L, Vagelos R et al. Cardiopulmonary exercise testing and prognosis in severe heart failure: 14 ml/kg/min revisited. Am. Heart J. (139), 78–84 (2000).
   PubMed Web of Science ®Google Scholar
• Pohwani AL, Murali S, Mathier MM et al. Impact of β-blocker therapy on functional capacity criteria for heart transplant listing. J. Heart Lung Transplant.22(1), 78–86 (2003).
   PubMed Web of Science ®Google Scholar
• Butler J, Khadim G, Paul K et al. Selection of patients for heart transplantation in the current era of heart failure therapy. J. Am. Coll. Cardiol.43(5), 787–793 (2004).
   PubMed Web of Science ®Google Scholar
• Nohria A, Tsang SW, Fang JC et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J. Am. Coll. Cardiol.41(10), 1797–1804 (2003).
   PubMed Web of Science ®Google Scholar
• Rohde LE, Beck da Silva L, Goldraich L et al. Reliability and prognostic value of traditional signs and symptoms in outpatients with congestive heart failure. Can. J. Cardiol.20(7), 697–702 (2004).
   PubMed Web of Science ®Google Scholar
• Troughton RW, Frampton C, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet355, 1126–1130 (2000).
   PubMed Web of Science ®Google Scholar
• Rohde LE, Palombini DV, Polanczyk CA, Goldraich L, Clausell N. A hemodynamically oriented echocardiography-based strategy in the treatment of congestive heart failure. J. Card. Fail.13(8), 618–625 (2007).
   PubMed Web of Science ®Google Scholar
• Stevenson LW, Tillisch JH, Hamilton M et al. Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than or equal to 20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am. J. Cardiol.66(19), 1348–1354 (1990).
   PubMed Web of Science ®Google Scholar
• Beck da Silva L, Mielniczuk L, Laberge M et al. Persistent orthopnea and the prognosis of patients in the heart failure clinic. Congest. Heart Fail.10, 177–180 (2004).
   PubMedGoogle Scholar
• Lund L, Aaronson K, Mancini D. Validation of peak exercise oxygen consumption and the heart failure survival score for serial risk stratification in advanced heart failure. Am. J. Cardiol.95, 734–741 (2005).
   PubMed Web of Science ®Google Scholar
• Allen LA, Yager JE, Funk MJ et al. Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure. JAMA299(21), 2533–2542 (2008).
   PubMed Web of Science ®Google Scholar
• Yancy C. Predicting life expectancy in heart failure. JAMA299, 2566–2567 (2008).
   PubMed Web of Science ®Google Scholar
• Stevenson LW, Hellcamp AS, Leier CV et al. Changing preferences for survival after hospitalization with advanced heart failure. J. Am. Coll. Cardiol.52(21), 1702–1708 (2008).
   PubMed Web of Science ®Google Scholar
• Yamokoski LM, Hasselblad V, Moser DM et al. Prediction of rehospitalization and death in severe heart failure by physicians and nurses of the ESCAPE trial. J. Card. Fail.13(1), 8–13 (2007).
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Haynes RB, Jaeschke RZ et al. Users’ guides to the medical literature: XXV. Evidence-based medicine: principles for applying the users’ guides to patient care. JAMA284(10), 1290–1296 (2000).
   PubMed Web of Science ®Google Scholar
• Stevenson LW. Design of therapy for advanced heart failure. Eur. J. Heart Fail.7, 323–331 (2005).
   PubMed Web of Science ®Google Scholar
• Stevenson LW. Clinical use of inotropic therapy for heart failure: looking backward or forward? part i: inotropic infusions during hospitalization. Circulation108, 367–372 (2003).
   PubMed Web of Science ®Google Scholar
• O’Connor CM, Gattis WA, Uretsky BF et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure insights from the Flolan International Randomized Survival Trial (FIRST). Am. Heart J.138, 78–86 (1999).
   PubMed Web of Science ®Google Scholar
• Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet361(9372), 1843–1848 (2003).
   PubMed Web of Science ®Google Scholar
• Packer M, Fowler MB, Roecker EB et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation106(17), 2194–2199 (2002).
   PubMed Web of Science ®Google Scholar
• Lewis EF, Johnson PA, Johnson W, Collins C, Griffin L, Stevenson LW. Preferences for quality of life or survival expressed by patients with heart failure. J. Heart Lung Transplant.20(9), 1016–1024 (2001).
   PubMed Web of Science ®Google Scholar
• Packer M, O’Connor CM, Ghali JK et al. Effect of amlodipine on morbidity and mortality in severe and chronic heart failure. New Engl. J. Med.335, 1107–1114 (1996).
   PubMed Web of Science ®Google Scholar